The development of a PDE9 inhibitor for heart failure encountered challenges in phase II trials. Two placebo-controlled trials, CYCLE-1 and CYCLE-2, investigated tovinontrine’s effectiveness in heart failure with reduced ejection fraction (HFrEF) and heart failure with preserved ejection fraction (HFpEF) respectively.
In CYCLE-1, the high dose (50 mg BID) of tovinontrine failed to significantly reduce NT-proBNP, while the medium dose (25 mg BID) showed a more promising, albeit non-significant, decrease. A post-hoc analysis revealed a favorable response with the low dose (2.5 mg BID), indicating an inverse dose response. CYCLE-2, testing 50 mg BID, also failed to reduce NT-proBNP, demonstrating a negative effect. CYCLE-1 enrolled 529 participants with an average age of 69, predominantly male (78%) and white (94%), who were on guideline-directed medical therapy, including sacubitril/valsartan in a majority. CYCLE-2 included 277 patients with an average age of 72, predominantly male (64%) and white (92%), also on guideline-directed medical therapy. Across all doses, plasma cGMP increased from baseline to week 12, while the placebo group experienced a decrease. A post-hoc analysis suggested that modest increases in plasma cGMP with tovinontrine may lead to greater reductions in NT-proBNP versus placebo. Treatment-emergent adverse events were observed, primarily mild, with minimal changes in blood pressure at 12 weeks. Renal changes were transient and reversible. Interest in PDE9 inhibition stems from observations that PDE9 expression is increased in heart failure, particularly in HFpEF. The CARDINAL-HF trial demonstrated that a PDE9 inhibitor raises cGMP elevation, with or without sacubitril/valsartan, and with no major safety concerns. The next phase, CYCLE-3, is planned for HFrEF, focusing on a lower tovinontrine dose to achieve less intense PDE9 inhibition and reduce cGMP elevation, potentially leading to greater NT-proBNP reduction.